Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) EBT Margin (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed EBT Margin for 6 consecutive years, with 2082800.0% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 29891818.0% to 2082800.0% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 712011.11% through Dec 2025, down 16334390.0% year-over-year, with the annual reading at 712011.11% for FY2025, 16334390.0% down from the prior year.
  • EBT Margin hit 2082800.0% in Q4 2025 for Lyell Immunopharma, down from 226580.0% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 23.42% in Q4 2022 to a low of 2139533.33% in Q3 2022.
  • Historically, EBT Margin has averaged 529825.03% across 5 years, with a median of 217160.15% in 2023.
  • Biggest five-year swings in EBT Margin: crashed -213775871bps in 2022 and later soared 192980933bps in 2023.
  • Year by year, EBT Margin stood at 1673.1% in 2021, then soared by 99bps to 23.42% in 2022, then plummeted by -1721920bps to 403261.54% in 2023, then plummeted by -342bps to 1783881.82% in 2024, then dropped by -17bps to 2082800.0% in 2025.
  • Business Quant data shows EBT Margin for LYEL at 2082800.0% in Q4 2025, 226580.0% in Q3 2025, and 548300.0% in Q2 2025.